<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875342</url>
  </required_header>
  <id_info>
    <org_study_id>0802009646</org_study_id>
    <nct_id>NCT00875342</nct_id>
  </id_info>
  <brief_title>Imaginal Exposure &amp; D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)</brief_title>
  <official_title>D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to evaluate the effects of D-cycloserine (DCS) combined with&#xD;
      cognitive-behavioral treatment with exposure therapy in a sample of patients who developed&#xD;
      posttraumatic stress disorder (PTSD) as a consequence of various traumas (e.g., motor vehicle&#xD;
      and accidents, burns and other injuries, combat, World Trade Center attack, etc.). In&#xD;
      addition, this study hopes to determine whether a common human genetic single nucleotide&#xD;
      polymorphism (SNP) in a growth factor, brain derived neurotrophic factor, BDNF SNP&#xD;
      (Val66Met), predicts treatment response to PTSD.&#xD;
&#xD;
      Patients living in areas that are not geographically proximal to the Weill-Cornell Medical&#xD;
      Center New York City campus will receive cognitive behavioral therapy using telemedicine&#xD;
      (videoconferencing technology).&#xD;
&#xD;
      Overall, this study aims 1) to determine if subjects administered DCS show a significantly&#xD;
      larger decrease in symptoms of PTSD as compared to those administered a placebo, 2) to&#xD;
      determine if subjects administered DCS show a decrease in PTSD symptomatology significantly&#xD;
      earlier (as measured by weeks) than those administered a placebo, 3) to determine if&#xD;
      differences in symptomatology are evident at a 6-month follow-up and indicate long-term&#xD;
      differences between groups, 4) to determine if the BDNF SNP predicts treatment response, 5)to&#xD;
      determine if it is feasible and acceptable to provide imaginal exposure (IE) therapy for PTSD&#xD;
      using videoconferencing technology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following an initial assessment evaluating eligibility for the study, eligible participants&#xD;
      will be randomly assigned to one of two treatment groups: imaginal exposure (IE) plus DCS&#xD;
      (100mg) or IE plus placebo (sugar pill). DCS is a broad spectrum antibiotic that has recently&#xD;
      been implicated as a cognitive enhancer and may enhance the treatment that occurs. The&#xD;
      participant, assessor and treating clinicians will be blinded to which pill the participant&#xD;
      is receiving. The dose of medication will need to be taken only on the days of therapy&#xD;
      sessions during which the exposure occurs (approximately 9 times). Both groups will be&#xD;
      treated with a standardized cognitive-behavioral exposure therapy protocol utilizing&#xD;
      gold-standard treatment, consisting of 12-14 weekly individual (one-on-one) sessions with a&#xD;
      highly qualified clinical psychologist. Treatment interventions include imaginal exposure,&#xD;
      graduated in vivo exposure, psycho-education, relaxation training, behavioral activation, and&#xD;
      cognitive restructuring. Assessments will occur prior to treatment, following sessions 3, 6&#xD;
      and 10, following completion of treatment, and 6 months after the conclusion of treatment. In&#xD;
      addition, all participants will be genotyped once for the BDNF SNP (Val66Met) using a&#xD;
      non-invasive saliva sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial is no longer enrolling due to priority of other non-pharmacologic PTSD trials.&#xD;
  </why_stopped>
  <start_date type="Actual">May 2008</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms of Posttraumatic Stress Disorder-Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>Immediately after the intervention, an average of 6 months</time_frame>
    <description>Clinician Administered PTSD Scale (CAPS). Total CAPS severity score range is 0-136. Higher values represent a worse outcome (i.e. greater severity of posttraumatic symptoms).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg on days of therapy session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCS</intervention_name>
    <description>1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)</description>
    <arm_group_label>D-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. English-speaking adults&#xD;
&#xD;
          2. Age 18-70&#xD;
&#xD;
          3. Survivor of a variety of traumas (e.g., motor vehicle and accidents, burns and others&#xD;
             injuries, combat, World Trade Center attack, etc.)&#xD;
&#xD;
          4. Diagnosed with PTSD&#xD;
&#xD;
          5. In good health. For persons with chronic injuries/conditions related to their&#xD;
             accidents, &quot;good health&quot; is defined as the injury being in a state of stabilization&#xD;
             and able to attend weekly outpatient sessions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current organic mental disorder&#xD;
&#xD;
          2. Schizophrenia or symptoms of psychosis/delusions&#xD;
&#xD;
          3. Bipolar disorder&#xD;
&#xD;
          4. Current substance abuse or dependence&#xD;
&#xD;
          5. Active suicidal/homicidal ideation, intent, or plan&#xD;
&#xD;
          6. Use of pacemaker&#xD;
&#xD;
          7. Significant health impairment, including renal disease&#xD;
&#xD;
          8. Taking oral anticoagulant medication, ethionamide (Trecator-SC), isoniazid (INH), or&#xD;
             anti-depressant medication&#xD;
&#xD;
          9. Hypersensitivity to cycloserine&#xD;
&#xD;
         10. History of seizures&#xD;
&#xD;
         11. Pregnant or currently trying to conceive, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JoAnn Difede, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.patss.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2021</results_first_posted>
  <disposition_first_submitted>February 16, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 21, 2021</disposition_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Traumatic Event</keyword>
  <keyword>Trauma Survivor</keyword>
  <keyword>Exposure Therapy</keyword>
  <keyword>PTSD DCS</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Telepsychiatry</keyword>
  <keyword>Telemental health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00875342/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>DCS: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
          <description>DCS: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.50" spread="11.75"/>
                    <measurement group_id="B2" value="40.71" spread="9.83"/>
                    <measurement group_id="B3" value="42.56" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAPS</title>
          <description>Clinician Administered PTSD Scale (CAPS). Total CAPS severity score range is 0-136. Higher values represent a worse outcome (i.e. greater severity of posttraumatic symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.20" spread="17.36"/>
                    <measurement group_id="B2" value="97.43" spread="17.37"/>
                    <measurement group_id="B3" value="97.31" spread="17.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptoms of Posttraumatic Stress Disorder-Clinician Administered PTSD Scale (CAPS)</title>
        <description>Clinician Administered PTSD Scale (CAPS). Total CAPS severity score range is 0-136. Higher values represent a worse outcome (i.e. greater severity of posttraumatic symptoms).</description>
        <time_frame>Immediately after the intervention, an average of 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>DCS: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Posttraumatic Stress Disorder-Clinician Administered PTSD Scale (CAPS)</title>
          <description>Clinician Administered PTSD Scale (CAPS). Total CAPS severity score range is 0-136. Higher values represent a worse outcome (i.e. greater severity of posttraumatic symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.31" spread="32.31"/>
                    <measurement group_id="O2" value="26.93" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
          <description>DCS: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program director</name_or_title>
      <organization>Weil Cornell Medical College</organization>
      <phone>212 821 0783</phone>
      <email>jdifede@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

